Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says

Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9